OGN Quote, Financials, Valuation and Earnings

Biogen has a net margin of 5.75% compared to Organon &'s net margin of 9.89%. Organon &'s return on equity of 220.72% beat Biogen's return on equity of 9.11%.

Organon & has a consensus price target of $17.17, signalling upside risk potential of 90.32%. On the other hand Biogen has an analysts' consensus of $172.25 which suggests that it could grow by 45.49%. Given that Organon & has higher upside potential than Biogen, analysts believe Organon & is more attractive than Biogen.

Organon & has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biogen has a beta of 0.125, suggesting its less volatile than the S&P 500 by 87.479%.

Organon & has a quarterly dividend of $0.28 per share corresponding to a yield of 12.42%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organon & pays 34.38% of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend. Organon &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & quarterly revenues are $1.5B, which are smaller than Biogen quarterly revenues of $2.4B. Organon &'s net income of $87M is lower than Biogen's net income of $240.5M. Notably, Organon &'s price-to-earnings ratio is 3.13x while Biogen's PE ratio is 11.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & is 0.37x versus 1.76x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 5.75% compared to Organon &'s net margin of -907.48%. Organon &'s return on equity of 220.72% beat Moderna's return on equity of -29.23%.

Organon & has a consensus price target of $17.17, signalling upside risk potential of 90.32%. On the other hand Moderna has an analysts' consensus of $46.96 which suggests that it could grow by 92.62%. Given that Moderna has higher upside potential than Organon &, analysts believe Moderna is more attractive than Organon &.

Organon & has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

Organon & has a quarterly dividend of $0.28 per share corresponding to a yield of 12.42%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organon & pays 34.38% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Organon &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & quarterly revenues are $1.5B, which are larger than Moderna quarterly revenues of $107M. Organon &'s net income of $87M is higher than Moderna's net income of -$971M. Notably, Organon &'s price-to-earnings ratio is 3.13x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & is 0.37x versus 3.02x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Internet Patents Corporation has a net margin of 5.75% compared to Organon &'s net margin of --. Organon &'s return on equity of 220.72% beat Internet Patents Corporation's return on equity of --.

Organon & has a consensus price target of $17.17, signalling upside risk potential of 90.32%. On the other hand Internet Patents Corporation has an analysts' consensus of -- which suggests that it could fall by --. Given that Organon & has higher upside potential than Internet Patents Corporation, analysts believe Organon & is more attractive than Internet Patents Corporation.

Organon & has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Internet Patents Corporation has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Organon & has a quarterly dividend of $0.28 per share corresponding to a yield of 12.42%. Internet Patents Corporation offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organon & pays 34.38% of its earnings as a dividend. Internet Patents Corporation pays out -- of its earnings as a dividend. Organon &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & quarterly revenues are $1.5B, which are larger than Internet Patents Corporation quarterly revenues of --. Organon &'s net income of $87M is higher than Internet Patents Corporation's net income of --. Notably, Organon &'s price-to-earnings ratio is 3.13x while Internet Patents Corporation's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & is 0.37x versus -- for Internet Patents Corporation. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 5.75% compared to Organon &'s net margin of 26.7%. Organon &'s return on equity of 220.72% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Organon & has a consensus price target of $17.17, signalling upside risk potential of 90.32%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $800.13 which suggests that it could grow by 46.1%. Given that Organon & has higher upside potential than Regeneron Pharmaceuticals, analysts believe Organon & is more attractive than Regeneron Pharmaceuticals.

Organon & has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.331%.

Organon & has a quarterly dividend of $0.28 per share corresponding to a yield of 12.42%. Regeneron Pharmaceuticals offers a yield of 0.16% to investors and pays a quarterly dividend of $0.88 per share. Organon & pays 34.38% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend. Organon &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & quarterly revenues are $1.5B, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Organon &'s net income of $87M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Organon &'s price-to-earnings ratio is 3.13x while Regeneron Pharmaceuticals's PE ratio is 13.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & is 0.37x versus 4.44x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.